See today's edition of
DailyUpdates in your
therapeutic area
Search all articles

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Related Industry Reports:

Application of the nuclear factor-kappaB inhibitor pyrrolidine dithiocarbamate for the treatment of endometriosis: an in vitro study.

Fertility and sterility 2010 Jun 18; In press

Link to PubMed abstract

Zhang J JJ, Xu Z ZM, Dai H HY, Ji X XQ, Duan Y YY, Zhang C CM, Qin D DY

Department of Obstetrics and Gynecology, Affiliated Hospital of Medical College of Qingdao University, Qingdao, Shandong, People's Republic of China.

This study demonstrated that pyrrolidine dithiocarbamate (PDTC), a potent nuclear factor-kappaB inhibitor, showed stronger inhibitory effects on nuclear factor-kappaB activation in endometriotic stromal cells than in normal endometrial stromal cells as determined by electrophoretic mobility shift assay and Western blot analysis. Pretreatment of endometriotic stromal cells with PDTC attenuated tumor necrosis factor-alpha-induced expressions of CD44s, matrix metalloproteinase-9, and vascular endothelial growth factor whereas reversed tumor necrosis factor-alpha-reduced expressions of tissue inhibitor of metalloproteinase-1 revealed by reverse transcriptase polymerase chain reaction and Western blot analysis, suggesting that PDTC may represent a novel therapeutic strategy for treatment of endometriosis.

Keywords: endometriosis